Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

ZBH

Unpacking Zimmer Biomet Stock – A Fundamental Analysis

Zimmer Biomet marked a 1.1% change today, compared to -1.0% for the S&P 500. Is it a good value at today's price of $92.64? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.

  • Zimmer Biomet belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19

  • The company's P/B ratio is 1.48

  • Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 20.6 based on its trailing 12 month price to earnings (EPS) of $4.5 per share

  • Its forward P/E ratio is 10.8, based on its forward earnings per share (EPS) of $8.6

  • Over the last four years, Zimmer Biomet has averaged free cash flows of $1.26 Billion, which on average grew 0.9%

  • ZBH's gross profit margins have averaged 11.7 % over the last four years and during this time they had a growth rate of 1.2 % and a coefficient of variability of 4674.42 %.

  • Zimmer Biomet has moved -20.4% over the last year compared to 9.4% for the S&P 500 -- a difference of -29.7%

  • ZBH has an average analyst rating of hold and is -14.71% away from its mean target price of $108.62 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS